Next Quarterly Earnings
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Protalix Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins. Protalix leverages a unique plant-based expression technology to produce innovative medicines for rare and serious diseases. The company is advancing medical biotechnology.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Protalix Biotherapeutics is scheduled to report its next quarterly earnings on 11/16/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Protalix Biotherapeutics last reported quarterly earnings on 8/12/2026 (Q2 2026). Earnings per share (EPS) came in at 0.05 USD.
Across its last 3 earnings reports, Protalix Biotherapeutics stock moved by ±7.8% on average the following day. The largest reaction was -20.8% on 03/18/2026; 2 of 3 reactions were positive.
Protalix Biotherapeutics has beaten analyst EPS estimates in 2 of its last 5 evaluated quarters (beat rate: 40%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 3 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.